Oura’s $2.2B IPO is mostly a payday for existing shareholders

Oura is seeking up to $2.2 billion in its IPO at $40-$44 per share, implying a market capitalization of up to $14.1 billion, but existing shareholders will receive about $1.53 billion of gross proceeds at the $42 midpoint versus $567 million for the company. Forerunner Ventures plans to sell its full 9.3% stake for roughly $1.20 billion, accounting for nearly 80% of secondary shares sold. Oura expects to use $526.4 million of estimated $532.6 million net primary proceeds to settle employee-share tax obligations, while membership revenue more than doubled to $240.5 million with an 89% gross margin and paying members are projected to reach 5.7 million by fiscal year-end.

Analysis

The key public-market issue is not growth quality but float quality: a sponsor-led exit creates meaningful first-day supply while contributing little incremental operating capital. With the primary proceeds effectively absorbed by IPO-related employee tax withholding, OURA enters trading without a materially larger investment budget; the valuation must therefore be supported by organic cash generation and execution rather than a post-listing growth-capital runway. Forerunner’s full exit removes a concentrated overhang, but its scale may require unusually strong institutional allocation demand to prevent weak aftermarket price discovery.

The earnings debate should center on whether high-margin membership can grow faster than hardware-driven customer acquisition costs. If recurring revenue penetration rises, OURA can plausibly earn a premium consumer-health multiple; if device replacement cycles lengthen or marketing expense must rise to sustain member additions, the business remains valued more like a premium wearables vendor. The relevant competitive pressure is not only Samsung and Apple hardware, but their ability to bundle health software into installed ecosystems at low marginal cost, which could cap standalone subscription pricing and retention over 6-18 months.

Near term, avoid extrapolating a strong IPO print into fundamental confirmation: limited float and index/ETF demand can distort the first several sessions. The more informative 1-3 month catalysts are the first public disclosure of churn, subscription attach rate, contribution margin after marketing, and guidance durability; absent these, the proposed valuation leaves little margin for deceleration. Contrarian view: the complete venture exit is cleaner than a recurring lockup overhang, but only if the book is broadly distributed rather than concentrated among momentum accounts.

Key Decisions for Investors

• Do not chase the opening print. Establish a watch entry only after 20-30 trading days, when allocation-related support fades and initial liquidity normalizes; require the stock to hold or reclaim the IPO midpoint with above-average volume.
• For a long, size OURA as a 6-12 month recurring-revenue conversion thesis, not a hardware momentum trade. Add only if the first earnings release shows membership growth outpacing sales, stable or improving gross margin, and no material increase in sales-and-marketing intensity; target 2:1 upside/downside from post-lockup support, with a stop on a guidance cut or evidence of rising churn.
• Use a relative-value hedge against consumer discretionary/wearables beta: long OURA only versus short XLY or a basket exposure to AAPL/Samsung-related consumer electronics where feasible. The hedge should be removed if OURA proves software-like retention, because the intended alpha is subscription mix expansion rather than sector demand.
• Monitor the first lockup expiration and quarterly cash-flow disclosures. A material decline in cash, elevated stock-based compensation dilution, or membership attach-rate stagnation would falsify the premium-multiple thesis and justify avoiding or shorting a post-IPO rally.